Dr. Matthew Carraro, M.D
NPI: 1437441052
Total Payments
$828,012
2024 Payments
$142,911
Companies
41
Transactions
1,017
Medicare Patients
957
Medicare Billing
$545,826
Payment Breakdown by Category
Other$624,969 (75.5%)
Consulting$123,394 (14.9%)
Travel$53,631 (6.5%)
Food & Beverage$17,153 (2.1%)
Research$8,474 (1.0%)
Education$390.30 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $623,720 | 227 | 75.3% |
| Consulting Fee | $123,394 | 41 | 14.9% |
| Travel and Lodging | $53,631 | 212 | 6.5% |
| Food and Beverage | $17,153 | 503 | 2.1% |
| Unspecified | $8,474 | 26 | 1.0% |
| Honoraria | $1,250 | 1 | 0.2% |
| Education | $390.30 | 7 | 0.0% |
Payments by Type
General
$819,537
991 transactions
Research
$8,474
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $405,160 | 375 | $0 (2024) |
| EMD Serono, Inc. | $166,023 | 173 | $0 (2024) |
| Biogen, Inc. | $123,485 | 185 | $0 (2024) |
| TG Therapeutics, Inc. | $73,000 | 52 | $0 (2024) |
| Genentech USA, Inc. | $34,557 | 34 | $0 (2024) |
| Mallinckrodt LLC | $10,009 | 15 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $6,924 | 30 | $0 (2024) |
| Genentech, Inc. | $1,896 | 3 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $1,750 | 1 | $0 (2022) |
| Janssen Scientific Affairs, LLC | $1,320 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $142,911 | 140 | TG Therapeutics, Inc. ($70,995) |
| 2023 | $80,944 | 122 | EMD Serono, Inc. ($59,558) |
| 2022 | $65,407 | 145 | EMD Serono, Inc. ($35,539) |
| 2021 | $64,764 | 43 | GENZYME CORPORATION ($28,684) |
| 2020 | $33,156 | 44 | Biogen, Inc. ($18,486) |
| 2019 | $134,392 | 141 | GENZYME CORPORATION ($101,296) |
| 2018 | $170,330 | 191 | GENZYME CORPORATION ($135,815) |
| 2017 | $136,107 | 191 | GENZYME CORPORATION ($102,980) |
All Payment Transactions
1,017 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $10.94 | General |
| Category: PAIN | ||||||
| 12/17/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $31.89 | General |
| 12/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $22.53 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: Neurology | ||||||
| 11/21/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $18.14 | General |
| Category: Neuroscience | ||||||
| 11/15/2024 | Biogen, Inc. | TYSABRI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,614.00 | General |
| Category: Neurology | ||||||
| 11/13/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,387.50 | General |
| Category: Immunology | ||||||
| 11/13/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | In-kind items and services | $1,043.00 | General |
| Category: Immunology | ||||||
| 11/13/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $108.95 | General |
| Category: Immunology | ||||||
| 11/12/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $930.00 | General |
| Category: Immunology | ||||||
| 11/06/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,387.50 | General |
| Category: Immunology | ||||||
| 11/06/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,488.00 | General |
| Category: Neurology | ||||||
| 11/06/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: Immunology | ||||||
| 10/31/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $22.01 | General |
| Category: PAIN | ||||||
| 10/30/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: Immunology | ||||||
| 10/29/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,712.50 | General |
| Category: Immunology | ||||||
| 10/29/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $17.03 | General |
| Category: Neuroscience | ||||||
| 10/25/2024 | Biogen, Inc. | TYSABRI (Biological) | Travel and Lodging | Cash or cash equivalent | $103.00 | General |
| Category: Neurology | ||||||
| 10/16/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | Cash or cash equivalent | $86.41 | General |
| Category: Immunology | ||||||
| 10/16/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | Cash or cash equivalent | $11.54 | General |
| Category: Immunology | ||||||
| 10/01/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: Neurology | ||||||
| 09/27/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: Immunology | ||||||
| 09/27/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $32.74 | General |
| 09/25/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: Central Nervous System | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $2,471 | 5 |
| A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) | GENZYME CORPORATION | $1,817 | 6 |
| An Extension Protocol for Multiple Scerlosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,Comparison of Alemtuzumab and Rebif? Efficacy in Multiple Sclerosis, Study One (CARE | GENZYME CORPORATION | $1,609 | 3 |
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $1,059 | 6 |
| An Extension Protocol for Multiple Sclerosis patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $564.44 | 2 |
| Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study Two (CARE-MS II): A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and Hig | GENZYME CORPORATION | $443.33 | 2 |
| Comparison of Alemtuzumab and Rebif? Efficacy in Multiple Sclerosis, Study Two (CARE-MS II): A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles ,of Intravenous Low- and | GENZYME CORPORATION | $333.33 | 1 |
| Comparison of alemtuzumab and Rebif efficacy in multiple sclerosis, study two (CARE-MS II): a phase 3, randomized, rater- and dose-blind study comparing two annual cycles of intravenous low- and high- | GENZYME CORPORATION | $176.67 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 330 | 10,706 | $1.2M | $462,705 |
| 2022 | 5 | 241 | 311 | $61,085 | $33,654 |
| 2021 | 5 | 202 | 282 | $81,285 | $30,060 |
| 2020 | 4 | 184 | 242 | $63,160 | $19,408 |
Total Patients
957
Total Services
11,541
Medicare Billing
$545,826
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2023 | 11 | 10,200 | $1.2M | $425,136 | 36.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 67 | 111 | $25,456 | $11,835 | 46.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 85 | 124 | $20,770 | $10,732 | 51.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 54 | 79 | $9,041 | $4,998 | 55.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 47 | 47 | $11,515 | $4,967 | 43.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 15 | 29 | $9,251 | $2,407 | 26.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $3,366 | $1,497 | 44.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 14 | 56 | $4,032 | $1,027 | 25.5% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 13 | 25 | $437.50 | $89.34 | 20.4% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 13 | 24 | $432.00 | $16.68 | 3.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 55 | 98 | $20,972 | $12,302 | 58.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 73 | 90 | $14,310 | $8,252 | 57.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 57 | 57 | $13,965 | $6,565 | 47.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 24 | 24 | $7,344 | $3,634 | 49.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 32 | 42 | $4,494 | $2,901 | 64.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 70 | 133 | $41,010 | $15,765 | 38.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 65 | 80 | $18,418 | $6,584 | 35.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 24 | 24 | $10,886 | $3,951 | 36.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 21 | 21 | $7,179 | $2,339 | 32.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 22 | 24 | $3,792 | $1,420 | 37.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 91 | 131 | $30,523 | $9,405 | 30.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 46 | 60 | $18,720 | $5,766 | 30.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 21 | 21 | $9,177 | $2,730 | 29.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 26 | 30 | $4,740 | $1,507 | 31.8% |
About Dr. Matthew Carraro, M.D
Dr. Matthew Carraro, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Charlotte, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2011. The National Provider Identifier (NPI) number assigned to this provider is 1437441052.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Carraro, M.D has received a total of $828,012 in payments from pharmaceutical and medical device companies, with $142,911 received in 2024. These payments were reported across 1,017 transactions from 41 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($623,720).
As a Medicare-enrolled provider, Carraro has provided services to 957 Medicare beneficiaries, totaling 11,541 services with total Medicare billing of $545,826. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Neurology
- Location Charlotte, NC
- Active Since 05/16/2011
- Last Updated 08/07/2023
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1437441052
Products in Payments
- LEMTRADA (Drug) $282,396
- Mavenclad (Drug) $82,683
- AUBAGIO (Drug) $76,830
- BRIUMVI (Drug) $71,060
- TYSABRI (Biological) $43,623
- MAVENCLAD (Drug) $38,786
- OCREVUS (Biological) $34,777
- TECFIDERA (Drug) $17,503
- Mavenclad (Biological) $10,295
- ACTHAR (Biological) $10,036
- KESIMPTA (Drug) $6,761
- Tysabri (Biological) $5,166
- DISEASE STATE (Drug) $5,026
- Evobrutinib $3,600
- Non-Covered Product (Drug) $1,515
- UPLIZNA (Drug) $1,300
- LEMTRADA (Biological) $836.04
- NURTEC ODT (Drug) $362.77
- NUPLAZID (Drug) $340.91
- UBRELVY (Drug) $182.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Charlotte
Dr. Keith Fehring, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $650,759
Student in an Organized Health Care Education/Training Program $650,759
Mr. Theodore Nyame, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $368,634
Student in an Organized Health Care Education/Training Program $368,634
Dr. Joshua Hunter, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $102,136
Student in an Organized Health Care Education/Training Program $102,136
Dr. Kenneth Weeks, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $82,342
Student in an Organized Health Care Education/Training Program $82,342
Dr. Scott O'neal, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $48,779
Student in an Organized Health Care Education/Training Program $48,779
Dr. Olanrewaju Jimoh, Md, Mba, MD, MBA
Student in an Organized Health Care Education/Training Program — Payments: $43,889
Student in an Organized Health Care Education/Training Program $43,889